Samer K. Khaled, MD, medical director of hematology and HCT Clinical Operations at City of Hope, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy (TA-TMA).

The complication of TA-TMA occurs posttransplant, and patients with this condition often have a poor prognosis with an increase in mortality and morbidity. Therefore, Khaled suggests recognizing this condition early to begin treatment as soon as possible. Some data show that early treatment with a complement blockade can improve the outcomes for these patients, according to Khaled.

Research for treating TA-TMA is still in its early stages and the treatment procedure depends on the physician recognition of the condition, says Khaled. In the pediatric space, there are more efforts into systematically looking or screening for the markers of TA-TMA to recognize the complication early, concludes Khaled.

Videos

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Samer K. Khaled, MD

Articles

Dr. Khaled on Recognition and Treatment of TA-TMA